株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

口腔粘膜炎 : パイプライン製品の分析

Oral Mucositis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 192750
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
口腔粘膜炎 : パイプライン製品の分析 Oral Mucositis - Pipeline Review, H1 2017
出版日: 2017年03月22日 ページ情報: 英文 91 Pages
概要

口腔粘膜炎は最も一般的な粘膜炎の一種で、がんの外科手術・化学療法・放射線治療の際に併発する衰弱性疾患です。主な症状として、口腔内部の色調異常や唾液分泌減退、粘膜構造の変化、唇・舌での浮腫の発生などがあります。主な治療法としては、口腔洗浄(マウスケア)や、口腔内部の創面切除(デブリードメント)などがあります。

当レポートでは、世界各国での口腔粘膜炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

口腔粘膜炎の概要

治療薬の開発

  • 口腔粘膜炎向けパイプライン製品:概要
  • 口腔粘膜炎向けパイプライン製品:比較分析

各企業で開発中の口腔粘膜炎治療薬

大学/研究機関で研究中の口腔粘膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

口腔粘膜炎治療薬:開発中の製品の一覧(企業別)

口腔粘膜炎治療薬:研究中の製品の一覧(大学/研究機関別)

口腔粘膜炎治療薬の開発に従事している企業

  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • 大塚ホールディングス
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

口腔粘膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

口腔粘膜炎治療薬:開発が休止状態の製品

口腔粘膜炎治療薬:開発が中止された製品

口腔粘膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9075IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oral Mucositis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oral Mucositis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oral Mucositis - Overview
  • Oral Mucositis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Oral Mucositis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Oral Mucositis - Companies Involved in Therapeutics Development
    • Cellceutix Corp
    • Clevexel Pharma SA
    • Colby Pharmaceutical Company
    • Galera Therapeutics Inc
    • Humanetics Corp
    • Onxeo SA
    • Oragenics Inc
    • Otsuka Holdings Co Ltd
    • Soligenix Inc
    • Spectrum Pharmaceuticals Inc
    • Spherium Biomed SL
  • Oral Mucositis - Drug Profiles
    • AG-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCD-600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0095 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HYLP-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rebamipide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
      • Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
      • Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Nov 21, 2016: U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis
      • Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
      • Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Sep 27, 2016: Galera Therapeutics Announces Presentation of One-Year Follow-up Data from a Phase 1b/2a Study of GC4419 In the Reduction of Severe Oral Mucositis
      • Sep 06, 2016: Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
      • Aug 30, 2016: Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
      • Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
      • Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
      • Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
      • May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
      • Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Oral Mucositis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Oral Mucositis - Pipeline by Cellceutix Corp, H1 2017
  • Oral Mucositis - Pipeline by Clevexel Pharma SA, H1 2017
  • Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2017
  • Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2017
  • Oral Mucositis - Pipeline by Humanetics Corp, H1 2017
  • Oral Mucositis - Pipeline by Onxeo SA, H1 2017
  • Oral Mucositis - Pipeline by Oragenics Inc, H1 2017
  • Oral Mucositis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Oral Mucositis - Pipeline by Soligenix Inc, H1 2017
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2017
  • Oral Mucositis - Dormant Projects, H1 2017
  • Oral Mucositis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Oral Mucositis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Oral Mucositis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top